Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DNTH, CGON, ORKA, JBIO, ELVN, and represent 70.88% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: Mobia Med (+$11M), IMUX (+$10M), SENS (+$9.1M), CGON (+$7.8M), ELVN (+$7.6M), JBIO (+$6.7M), TEM, KPTI, NVCT, GPCR.
- Started 9 new stock positions in Alamar Biosciences, IMUX, Scynexis, NVCT, Mobia Med, Kailera Therapeutics, Avalyn Pharma, SENS, EVMN.
- Reduced shares in these 10 stocks: Immunic (-$6.4M), HUM (-$5.9M), MDT, , SCYX, NTRA, , KVUE, RVMD, HIMS.
- Sold out of its positions in ABVX, ACAD, AVR, ABUS, CNC, CORT, HIMS, HUM, Immunic, KVUE. MLTX, NTRA, RVMD, SCYX, UNH, ICLR.
- Avidity Partners Management was a net buyer of stock by $48M.
- Avidity Partners Management has $624M in assets under management (AUM), dropping by -33.26%.
- Central Index Key (CIK): 0001791827
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avidity Partners Management
Avidity Partners Management holds 45 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 32.8 | $205M | 2.1M | 97.48 |
|
|
| Cg Oncology (CGON) | 15.9 | $99M | +8% | 1.4M | 71.05 |
|
| Oruka Therapeutics (ORKA) | 11.6 | $72M | 760k | 95.17 |
|
|
| Jade Biosciences Com New (JBIO) | 6.1 | $38M | +21% | 1.7M | 22.22 |
|
| Enliven Therapeutics (ELVN) | 4.5 | $28M | +37% | 550k | 50.75 |
|
| Perspective Therapeutics Com New (CATX) | 3.4 | $22M | +4% | 6.3M | 3.41 |
|
| Aktis Oncology (AKTS) | 2.5 | $16M | +3% | 484k | 32.23 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 1.7 | $11M | 70k | 152.82 |
|
|
| Mobia Med Common Stock | 1.7 | $11M | NEW | 798k | 13.40 |
|
| Repligen Corporation (RGEN) | 1.7 | $11M | 78k | 136.44 |
|
|
| Immunic Com New (IMUX) | 1.6 | $10M | NEW | 670k | 15.37 |
|
| Senseonics Hldgs (SENS) | 1.5 | $9.1M | NEW | 1.6M | 5.68 |
|
| Karyopharm Therapeutics Com New (KPTI) | 1.4 | $9.0M | +99% | 925k | 9.77 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 1.1 | $6.8M | 200k | 33.88 |
|
|
| Dex (DXCM) | 1.1 | $6.7M | +11% | 100k | 67.35 |
|
| Tempus Ai Cl A (TEM) | 1.0 | $6.1M | +320% | 105k | 57.93 |
|
| Medtronic SHS (MDT) | 0.9 | $5.5M | -30% | 70k | 78.23 |
|
| Vir Biotechnology (VIR) | 0.8 | $5.3M | -16% | 519k | 10.19 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.8 | $5.3M | +226% | 98k | 53.67 |
|
| Encompass Health Corp (EHC) | 0.7 | $4.2M | 42k | 101.08 |
|
|
| Tenax Therapeutics Com New (TENX) | 0.6 | $3.9M | +23% | 266k | 14.55 |
|
| Nuvectis Pharma (NVCT) | 0.6 | $3.7M | NEW | 200k | 18.39 |
|
| Insulet Corporation (PODD) | 0.6 | $3.7M | +140% | 24k | 152.25 |
|
| Boston Scientific Corporation (BSX) | 0.5 | $3.4M | +33% | 80k | 42.68 |
|
| Satellos Bioscience (MSLE) | 0.5 | $3.0M | 388k | 7.78 |
|
|
| Alamar Biosciences Common Stock | 0.5 | $3.0M | NEW | 110k | 27.09 |
|
| Context Therapeutics (CNTX) | 0.4 | $2.8M | 5.0M | 0.55 |
|
|
| Gilead Sciences (GILD) | 0.4 | $2.5M | 20k | 126.34 |
|
|
| Charles River Laboratories (CRL) | 0.4 | $2.3M | 10k | 226.79 |
|
|
| Phathom Pharmaceuticals (PHAT) | 0.3 | $2.2M | -19% | 200k | 10.85 |
|
| Avalyn Pharmaceuticals Com Shs | 0.3 | $2.0M | NEW | 60k | 32.92 |
|
| Kailera Therapeutics Common Stock | 0.3 | $1.8M | NEW | 80k | 22.03 |
|
| Genmab A/s Sponsored Ads (GMAB) | 0.2 | $1.4M | 50k | 27.47 |
|
|
| Intellia Therapeutics (NTLA) | 0.2 | $1.3M | 75k | 16.92 |
|
|
| Corvus Pharmaceuticals (CRVS) | 0.2 | $1.2M | -30% | 80k | 14.94 |
|
| Oddity Tech Shs Cl A (ODD) | 0.2 | $1.1M | 70k | 15.13 |
|
|
| Scynexis | 0.2 | $1.1M | NEW | 260k | 4.07 |
|
| Evommune Com Shs (EVMN) | 0.2 | $997k | NEW | 75k | 13.29 |
|
| Abbott Laboratories (ABT) | 0.1 | $907k | 10k | 90.74 |
|
|
| Bridgebio Pharma (BBIO) | 0.1 | $745k | 10k | 74.48 |
|
|
| Peloton Interactive Cl A Com (PTON) | 0.1 | $591k | -50% | 100k | 5.91 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.1 | $433k | 15k | 28.88 |
|
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.1 | $334k | 44k | 7.62 |
|
|
| Savara (SVRA) | 0.0 | $308k | 50k | 6.16 |
|
|
| Trevi Therapeutics (TRVI) | 0.0 | $124k | 6.7k | 18.65 |
|
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2026 Q2 filed Aug. 14, 2026
- Avidity Partners Management 2026 Q1 amended filed May 28, 2026
- Avidity Partners Management 2026 Q1 filed May 13, 2026
- Avidity Partners Management 2025 Q4 filed Feb. 13, 2026
- Avidity Partners Management 2025 Q3 filed Nov. 14, 2025
- Avidity Partners Management 2025 Q2 filed Aug. 14, 2025
- Avidity Partners Management 2025 Q1 filed May 15, 2025
- Avidity Partners Management 2024 Q4 filed Feb. 14, 2025
- Avidity Partners Management 2024 Q3 filed Nov. 14, 2024
- Avidity Partners Management 2024 Q2 filed Aug. 14, 2024
- Avidity Partners Management 2024 Q1 filed May 15, 2024
- Avidity Partners Management 2023 Q4 filed Feb. 14, 2024
- Avidity Partners Management 2023 Q3 filed Nov. 14, 2023
- Avidity Partners Management 2023 Q2 filed Aug. 14, 2023
- Avidity Partners Management 2023 Q1 filed May 15, 2023
- Avidity Partners Management 2022 Q4 filed Feb. 14, 2023